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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.02.057Objective: This study compared hemodynamic function and clinical events in
consecutive patients randomly assigned to receive a wholly supra-annular replace-
ment valve or a valve with an intra-annular component.
Methods: Fifty-two patients with an average age of 62 years (range 40-74 years)
were sized for both a CarboMedics Top Hat valve (CarboMedics Inc, Austin, Tex)
and an MCRI On-X valve (Medical Carbon Research Institute, LLC, Austin, Tex)
before random assignment to receive either valve type. Echocardiographic and
clinical assessments were performed in the immediate postoperative period and at 1
year.
Results: The mean effective orifice areas were 1.41  0.42 cm2 for the Top Hat and
2.17  0.78 cm2 for the On-X (P  .0001). The mean pressure differences were
12.2  4.4 mm Hg and 6.9  3.6 mm Hg, respectively (P  .0001). New York
Heart Association functional class was better with the On-X than the Top Hat
valves, but there were no differences in clinical events, regression of left ventricular
mass, or measures of hemolysis.
Conclusion: The partially intra-annular MCRI On-X valve was hemodynamically
superior to the wholly supra-annular CarboMedics Top Hat valve. However, there
were no differences in early clinical outcomes between the two valve types.
Most surgeons try to obtain the best possible hemodynamic result afteraortic valve replacement surgery in the belief that this optimizes func-tional recovery and survival.1,2 Bileaflet valves are the least obstructive
mechanical design3 but may still cause clinically significant resistance in the small
sizes because the sewing ring reduces the area available for flow.4,5 Manufacturers
have therefore developed enhanced-performance intra-annular valves by reducing
the bulk of the sewing ring. Another solution is to raise the cuff above the tissue
annulus while at the same time retaining an intra-annular component (Figure 1, A)
as in the MCRI On-X (Medical Carbon Research Institute, LLC, Austin, Tex) valve
and AP-ATS valve. Finally, the whole of the valve can be placed in a supra-annular
position so that the tissue annulus contains no valve parts and the orifice of the valve
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B). An examples of this valve type is the CarboMedics Top
Hat valve (CarboMedics Inc, Austin, Tex).
We confirmed6 that a larger geometric orifice is possible
in vitro with the wholly supra-annular CarboMedics Top
Hat valve than with the MCRI On-X valve. However, the
extended housing of the intra-annular component of the
On-X valve is designed to reduce the pressure drop across
the orifice. It is possible that this design feature might
compensate for any tendency toward higher pressure differ-
ences as a result of the smaller geometric orifice. The
purpose of this study was to compare early hemodynamic
function and clinical events in patients randomly assigned to
receive either the MCRI On-X or CarboMedics Top Hat
valve.
Methods
Patients
A total of 52 consecutive patients scheduled to undergo aortic
Figure 1. Diagram of different implantation positions for supra-
annular valves. A, Partially intra-annular valve such as On-X.
Sewing ring is supra-annular, but part of housing is implanted
within annulus. B, Wholly supra-annular valve such as Top Hat.
Diameter (a) represents internal diameter of orifice, and diameter
between points b and b= represents maximum diameter of supra-
annular portion of valve. Patient tissue annulus diameter is di-
ameter of annulus after débridement. For On-X, this is equivalent
to outer diameter of intra-annular portion of housing. For Top Hat,
it can be equivalent to inner diameter (a), provided that maximum
supra-annular diameter (b to b=) is then able to fit within aortic
root.valve replacement with a mechanical valve were randomly
760 The Journal of Thoracic and Cardiovascular Surgery ● Septassigned to receive either the On-X valve (n  27) or the
CarboMedics supra-annular Top Hat valve (n  25). The mean
age was 62 years (range 40-74 years), and 31 (60%) were male.
The disease requiring surgery was dominant stenosis in 36
patients, dominant regurgitation in 11, and mixed disease in 5.
No patient had preoperative endocarditis or a coexistent condi-
tion with significant mortality. Two patients were discharged
early, and 3 patients died within 1 year. Predischarge echocar-
diograms were therefore available for 50 patients, and echocar-
diograms at 1 year were available for 49 patients. Demographic
data in the On-X and Top Hat groups were similar, except that
there were more men in the On-X group (Table 1). The study
was approved by the local committee on ethical practice, and all
patients gave written, informed consent.
Surgery
There were 11 associated coronary artery bypass grafting proce-
dures and 4 mitral replacements, divided evenly between the two
groups. No patient required aortoplasty. Before the randomization
envelope was opened, the patients were sized for both designs of
valve with the sizers provided by the manufacturers. Both sets of
sizers incorporate models of the valve to be implanted, and these
vary according to the label size of the valve (Table 2). Table 2
displays label size versus the theoretic tissue annulus diameter
modeled in vitro with machined polypropylene blocks,6 the geo-
metric orifice area,6 and the maximum diameter of the supra-
annular portion of the valve measured with a previously validated6
vernier caliper (Mitutoya RS 548-710; Mitutoya, Japan). There is
no sizer for the 27/29 On-X. In each case, the surgeon selected a
label size determined by the largest sizer that could be accommo-
dated in the aortic root after excision of the diseased valve and full
TABLE 1. Demographic data
Top Hat
(n  25)
On-X
(n  27)
Age (y, mean and range) 61 (50-72) 62 (40-74)
Male/female ratio 14:11 17:10
Body surface area (m2, mean  SD) 1.82  0.21 1.87  0.31
Left ventricular outflow diameter
(cm, mean  SD)
2.05 (0.26) 2.10 (0.22)
Associated mitral replacement (No.) 2 (8%) 2 (7%)
Associated coronary artery bypass
grafting (No.)
6 (24%) 5 (19%)
Preoperative NYHA class (No.)
Class I 5 (20%) 3 (11%)
Class II 10 (40%) 12 (44%)
Class III 9 (36%) 10 (37%)
Class IV 1 (4%) 2 (8%)
Preoperative aortic stenosis (No.) 18 (72%) 19 (70%)
Aortic regurgitation (No.) 6 (24%) 5 (19%)
Mixed aortic valve disease (No.) 1 (4%) 3 (11%)
Left ventricular hypertrophy (No.) 15 (60%) 13 (48%)
Left ventricular ejection fraction
40% (No.)
2 (8%) 1 (4%)
NYHA, New York Heart Association.débridement of calcium. The limiting factor in sizing both types of
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the recipient aortic root, as determined by the rigid valve sizer. For
those receiving a Top Hat valve, the mean (SD) label size was
23.4  2.2, which was not statistically significantly different from
the mean size (23.0  2.5) had the On-X had been implanted
instead. For those receiving an On-X valve, the mean size was 23.7
 2.1, whereas it would have been 23.7  2.2 had the Top Hat
been chosen instead (difference not significant). The difference
between the sizes of Top Hat and On-X valves actually implanted
was not statistically significant.
Echocardiography
Studies were performed preoperatively, immediately before hos-
pital discharge, and at 1 year (11-14 months). An ATL HDI 3000
(ATL Ultrasound, Bothell, Wash) was used with a 3-2 20-mm
duplex probe and 1.9-MHz continuous-wave stand-alone probe.
Effective orifice area was calculated with the classic form of the
continuity equation incorporating the ratio of subaortic to transaor-
tic systolic velocity time integral. The mean transprosthetic pres-
sure difference was calculated from the long form of the modified
Bernoulli equation. Left ventricular mass was calculated from a
standard formula,7 and sex-related criteria for left ventricular hy-
pertrophy8 were applied.
Clinical Follow-up
Clinical data were recorded preoperatively, before discharge, and
at 1 year. Clinical events were defined by standard criteria9 ac-
cording to occurrence before 30 days and between 30 days and one
year. Blood was drawn preoperatively and at 12 months to measure
lactate dehydrogenase (LDH), haptoglobin, bilirubin, and hemo-
globin levels and the reticulocyte count.
Analysis
Mean and SD values were calculated. Continuous variables were
compared with unpaired t tests, and discrete variables were com-
pared with the Fisher exact test. The 27/29 MCRI On-X was
treated as a 27 valve for comparison with the labeled size of the
CarboMedics Top Hat valve. We also recorded the proportion of
patients in whom the LDH level was above the normal range
TABLE 2. Valve measurements
In vitro tissue
annulus diameter
(mm)*
Maximum
external
diameter of sizer
(mm)†
Geometric orifice
area (mm2)*
Label size Top Hat On-X Top Hat On-X Top Hat On-X
19 17 20 22.9 22.0 160 222
21 18 22.5 25.2 24.0 208 280
23 19.5 24.5 27.5 26.0 256 343
25 21.5 26.5 30.6 28.0 316 405
27 24 26.5 32.7 __ 384 405
*These measures taken from Chambers and colleagues.6 The geometric
orifice area and the internal diameter (a in Figure 1) are measured from the
orifice omitting the leaflets. †Measured from point b to b= in Figure 1, A
and B.(286-580 U/L), the haptoglobin level was below the normal range
The Journal of Thoraci(30-200 mg/dL), and the reticulocyte count was above the normal
range (40-130  109 cells/L).
Results
Hemodynamic Function
The frequencies of labeled sizes are given in Table 3. The
CarboMedics Top Hat group was relatively more obstruc-
tive than the MCRI On-X group (Table 4), with a mean
pressure drop of 12.2 mm Hg versus 6.9 mm Hg (P 
.0001) and an effective orifice area of 1.41 cm2 versus 2.17
cm2 (P  .0001). Results by labeled size are given in Tables
5A through 5C. Preoperative left ventricular mass indices
were 143.5  61.2 g/m2 for the Top Hat and 139.8  51.6
g/m2 for the On-X. At 1 year, left ventricular mass indices
had fallen to 101.9  53.5 g/m2 in the Top Hat group and
95.9  44.1 g/m2 in the On-X group. The falls were 41.6
g/m2 for the Top Hat and 43.9 g/m2 for the On-X (difference
not significant).
Clinical Follow-up
Clinical events. There were no differences in the fre-
quency of clinical events (Table 6). There was 1 death
before 30 days in each group (total early mortality 3.8%)
and 1 death in the Top Hat group between 30 days and 1
year. There were no strokes before 30 days in either group
and 1 between 30 days and 1 year in the Top Hat group.
There were no transient ischemic attacks in the Top Hat
group and 2 in the On-X group, 1 before 30 days and 1
between 30 days and 1 year. There were no instances of
myocardial infarction, endocarditis, valve thrombosis, or
valve failure.
Functional class. The New York Heart Association
(NYHA) functional classes before surgery were similar
between the groups (Table 1). At 1 year after surgery, 16 of
TABLE 3. Valves implanted at each labeled size
Label size Top Hat On-X Proportion of total
19 2 3 9.6%
21 5 4 17.3%
23 10 7 32.7%
25 6 10 30.8%
27 2 3 9.6%
TABLE 4. Predischarge hemodynamic results
Label size Top Hat On-X P value
Peak velocity (m/s) 2.39 0.39 1.94 0.44 .0001
Peak pressure drop (mm Hg) 22.55 7.51 14.91 6.75 .0001
Mean pressure drop (mm Hg) 12.18 4.37 6.88 3.58 .0001
Effective orifice area (cm2) 1.41 0.42 2.17 0.78 .0001
Values are mean  SD.23 patients in the Top Hat group (70%) were in class I, and
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On-X group (92%) were in class I, and 2 (8%) were in class
II. The difference between the valve types was statistically
significant (P  .039; Table 7).
Blood Results
The LDH level increased by a mean of 169 U/L (range37
to 559 U/L) for the On-X valves and 261 U/L (range 14
to 544 U/L) for the Top Hat valves (P  .069). In the Top
Hat group, there was a low haptoglobin level before surgery
in 10%, compared with 68% after surgery; in the On-X
group, there was a low haptoglobin level in 29% before
surgery, compared with 72% after surgery. In the Top Hat
group, the LDH level was high in 19% before and 85% after
surgery; in the On-X group, these proportions were 30%
before and 64% after.
At 1 year after surgery, there were 9 patients in the Top
Hat group and 8 in the On-X group with a combination of
a raised LDH level, low haptoglobin level, and normal
reticulocyte count. There were 2 patients, both with Top Hat
TABLE 5A. Peak velocities in Top Hat and On-X valves by
labeled size
Label size Top Hat On-X
19 2.85 2.20
21 2.45 0.44 2.37
23 2.34 0.51 2.23 0.31
25 2.32 0.16 1.62 0.35
27 2.20 1.70
Values are mean  SD.
TABLE 5B. Mean pressure differences in Top Hat and On-X
valves by labeled size
Label size Top Hat On-X
19 18.3 9.70
21 13.38 4.64 10.13
23 11.76 5.18 8.81 3.56
25 10.36 2.47 4.47 2.67
27 9.87 4.70
Values are mean  SD.
TABLE 5C. Effective orifice areas in Top Hat and On-X
valves by labeled size
Label size Top Hat On-X
19 1.05 1.22
21 1.17 0.23 1.90
23 1.37 0.34 1.78 0.34
25 1.61 0.32 2.37 0.37
27 1.94 2.55
Values are mean  SD.valves, with a high LDH level and a raised reticulocyte
762 The Journal of Thoracic and Cardiovascular Surgery ● Septcount, 1 with a normal haptoglobin level and the other with
a low haptoglobin level. However, no patient in either group
had a low hemoglobin level or a significantly raised biliru-
bin level.
Discussion
The orifice of the CarboMedics supra-annular Top Hat
valve is expected to approximate that of the patient tissue
annulus (Figure 1, B). In contrast, the On-X valve housing
is partially intra-annular, so that its internal orifice must be
smaller than the patient tissue annulus (Figure 1, A). The
main aim of this study was to see whether the flared inlet
and elongated housing could offset this potential hemody-
namic disadvantage. In fact, the On-X proved hemodynam-
ically superior to the Top Hat valve.
The expectation when two types of valve are compared is
that sizing will be based on the patient tissue annulus. In an
in vitro study,6 in which the annulus was modeled by a
machined polypropylene block, a CarboMedics Top Hat
valve corresponded to an On-X valve two sizes smaller.
However, the in vitro model did not incorporate an aortic
root, and the results of this study show that the label sizes of
both valves were limited by the size of the supra-annular
portions of both valves, rather than by the tissue annulus.
Table 2 shows that for a given in vitro annulus diameter, a
Top Hat approximately two sizes larger than an On-X could
be implanted. For example, the 23 Top Hat fits a 19.5 mm
annulus, and the 19 On-X fits a 20 mm annulus. However
the supra-annular diameter, as shown by the sizer, is 27.5
mm for the 23 Top Hat and only 22.0 mm for the 19 On-X.
In fact, for a given label size, the supra-annular diameter of
the Top Hat is between 0.9 and 2.6 mm larger than that of
the On-X valve. We believe this explains why we found
similar label sizes when each patient was sized for both
valve types. Because of differences in sizing convention, the
orifice area is larger for the On-X than the Top Hat for a
given label size. In this study, the mean geometric orifice
area for the Top Hat valves actually implanted was 2.63 
0.59 cm2, versus 3.50 0.65 cm2 (P .0001) for the On-X.
In clinical practice, factors other than aortic root size may
TABLE 6. Clinical events
Top Hat On-X
Death, 30 d 1 1
Death, 30 d to 12 mo 1 0
Stroke, 30 d 0 0
Stroke, 30 d to 12 mo 1 0
Transient ischemic attack, 30 d 0 1
Transient ischemic attack, 30 d to 12 mo 0 1
Hemorrhage, 30 d 1 0
Hemorrhage, 30 d to 12 mo 0 1determine label size. A heavily calcified annulus may limit
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housing, or a low left coronary ostium may limit the size of
Top Hat valve.
This is the first randomized comparison of the Top Hat
and On-X valves. However, examination of previous clini-
cal studies10,11 shows evidence that the apparent label size
advantage of the Top Hat is not fully realized. Those stud-
ies10,11 reporting a size advantage for the Top Hat relative to
the standard CarboMedics valve do in fact show downsizing
of the Top Hat by 3 to 4 mm in comparison with in vitro
data.6 In one study,10 the mean labeled size for the Top Hat
was 20.8, versus 18.9 for the standard valve. However, a
standard size 19 valve fits a patient tissue annulus about
21.5 mm in diameter,6 which according to in vitro data6
would be expected to take a Top Hat size 25 rather than only
20.8. Such size comparisons are more in keeping with the
results of this study than with expectations from in vitro
work.
Other evidence suggests that our sizing was appropriate.
We implanted substantially larger Top Hat valves than in a
study of 693 patients from five centers in the United States12
and another of 127 patients from Spain.10 The proportion of
larger valves (size 25 and 27), was 40% in our study, versus
only 15% and 0% in the other studies.10,12 In contrast, the
proportion of smaller valves (size 19 and 21) was only 28%
in our study, versus 52% and 77%.10,12 Although body
surface area was not given for these other two studies, it is
unlikely that the patients were significantly smaller than
ours.
Clinical Results
The incidence of clinical events was low, with an early
mortality of 2.8% and no myocardial infarction, endocardi-
tis, valve thrombosis, or valve failure. This is consistent
with previous reports of both the On-X13,14 and Top
Hat,10,12,15 although no other randomized comparisons ex-
ist. We showed no significant differences between the
groups. This study was small, however, and not powered to
detect small differences in clinical events.
There was no difference in the degree of regression of
left ventricular mass, despite the statistically significant
difference in hemodynamic function. Other studies also
TABLE 7. Postoperative NYHA functional class
Top Hat
30 d 6 mo
Class I 21 (88%) 19 (83%) 16
Class II 2 (8%) 4 (17%) 7
Class III 1 (4%) 0 (0%) 0
Class IV 0 (0%) 0 (0%) 0
NYHA, New York Heart Association.show a lack of congruence between hemodynamic function
The Journal of Thoraciand left ventricular mass.16,17 This could be related to the
poor repeatability of unidimensional echocardiography rel-
ative to magnetic resonance imaging,18 so that small differ-
ence in left ventricular mass could have been missed. It may
also have been caused by the presence of other determinants
of left ventricular mass.19
Previous studies have commented on a low incidence
of hemolysis for the On-X relative to other valves13,20
according to historical data.21,22 However, there have
been no previous randomized comparisons. In fact, al-
though there was a smaller increase in LDH from before
surgery to 1 year in the On-X group than in the Top Hat
group, there were no statistically significant differences
between the groups. No patient in either group had ane-
mia or a raised bilirubin level.
Functional class was significant better with the On-X
valves than with the Top Hat valves. No patient was in
NYHA functional class III or IV, but 30% with a Top Hat
valve as opposed to only 8% with an On-X valve were in
NYHA functional class II, and 70% and 92%, respectively
were in NYHA functional class I. It is possible that this
reflects the difference in hemodynamic function, but it is
more likely to be a statistical variant.
Limitations
The population sizes were small, and the follow-up was
only for 1 year. Concomitant procedures might ideally have
been excluded, but the small number of patients with con-
comitant mitral surgery and those with coronary bypass
grafting were evenly divided between the two groups. Fur-
thermore, there were no statistically significant differences
in demographic characteristics at baseline. Nevertheless,
our power to comment on clinical events, NYHA functional
class, and regression of left ventricular mass is inevitably
limited. However, the population size is not expected to
affect our general conclusions about valve size and hemo-
dynamic performance.
Conclusion
In a randomized comparison, the MCRI On-X valve with a
partially intra-annular housing had a better hemodynamic
On-X
30 d 6 mo 1 y
) 24 (92%) 25 (96%) 24 (92%)
) 2 (8%) 1 (4%) 2 (8%)
0 (0%) 0 (0%) 0 (0%)
0 (0%) 0 (0%) 0 (0%)1 y
(70%
(30%
(0%)
(0%)performance than the wholly supra-annular CarboMedics
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implanted was limited by the diameter of the sizer within
the aortic root, which was larger for the Top Hat than for the
On-X. There were no statistically significant differences in
clinical event rate, hemolysis, or regression of left ventric-
ular hypertrophy at 1 year.
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